By Frank Prenesti
Date: Friday 10 Sep 2021
LONDON (ShareCast) - (Sharecast News) - Clinical stage biotherapeutics firm PureTech Health on Friday said its founded entity, Vor Biopharma, had won US fast track approval for its leukaemia treatment.
The US Food and Drug Administration granted the designation to VOR33, a hematopoietic stem cell therapeutic candidate for the treatment of acute myeloid leukaemia.
Email this article to a friend
or share it with one of these popular networks:
Currency | UK Pounds |
Share Price | 162.00p |
Change Today | 0.20p |
% Change | 0.12 % |
52 Week High | 237.50p |
52 Week Low | 140.40p |
Volume | 496,505 |
Shares Issued | 239.42m |
Market Cap | £387.86m |
Beta | 0.94 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:43 | 3,441 @ 162.00p |
16:29 | 493 @ 162.60p |
16:29 | 17 @ 162.60p |
16:29 | 153 @ 162.60p |
16:28 | 659 @ 162.60p |
Chair | Raju Kucherlapati |
CEO | Bharatt Chowrira |
You are here: research